Guggenheim Bullish on Core Drug Obefazimod's Prospects, Assigns 'Buy' Rating to Abivax (ABVX.US)-To The Moon - Tiger Brokers Online Investing Community - To The Moon

Like
Comment
Favorite

Guggenheim Bullish on Core Drug Obefazimod's Prospects, Assigns 'Buy' Rating to Abivax (ABVX.US)

Stock News2025-12-29

Prior to French biotech firm Abivax (ABVX.US) releasing data on its core drug obefazimod, investment bank Guggenheim raised the company's target stock price from $150 to $175 and assigned a "Buy" rating. Analyst Yatin Suneja stated that this adjustment is based on optimistic prospects for the upcoming 44th-week maintenance period data readout of its core drug obefazimod. On December 15, Abivax announced its Q3 2025 financial results. The company reported revenue of $2.4 million, exceeding market expectations by $1.06 million. However, the quarterly net loss per share totaled $1.68. The company's net loss for the first nine months widened to €254.1 million, up from €136.9 million in the same period of 2024. The company's financial activities reflect an increased focus on its lead drug candidate, obefazimod, a first-in-class oral miR-124 enhancer. Research and development expenses rose to €133.4 million, primarily driven by advancements in the ABTECT Phase III program for ulcerative colitis and the ENHANCE-CD Phase IIb trial for Crohn's disease. Abivax is gearing up for several key milestones in 2026. The primary results of the ABTECT maintenance trial are expected to be announced in Q2 2026, which will provide the final clinical basis for the planned New Drug Application (NDA) submission to the U.S. FDA in the second half of 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Like

Report

Comment

empty

No comments yet

Most Discussed

7x24

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1154069927?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-29 15:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1154069927","market":"hk","top_or_hot":-1,"title":"Guggenheim Bullish on Core Drug Obefazimod's Prospects, Assigns 'Buy' Rating to Abivax (ABVX.US)","media":"Stock News","content":"<p>Prior to French biotech firm Abivax (ABVX.US) releasing data on its core drug obefazimod, investment bank Guggenheim raised the company's target stock price from $150 to $175 and assigned a \"Buy\" rating. Analyst Yatin Suneja stated that this adjustment is based on optimistic prospects for the upcoming 44th-week maintenance period data readout of its core drug obefazimod. On December 15, Abivax announced its Q3 2025 financial results. The company reported revenue of $2.4 million, exceeding market expectations by $1.06 million. However, the quarterly net loss per share totaled $1.68. The company's net loss for the first nine months widened to €254.1 million, up from €136.9 million in the same period of 2024. The company's financial activities reflect an increased focus on its lead drug candidate, obefazimod, a first-in-class oral miR-124 enhancer. Research and development expenses rose to €133.4 million, primarily driven by advancements in the ABTECT Phase III program for ulcerative colitis and the ENHANCE-CD Phase IIb trial for Crohn's disease. Abivax is gearing up for several key milestones in 2026. The primary results of the ABTECT maintenance trial are expected to be announced in Q2 2026, which will provide the final clinical basis for the planned New Drug Application (NDA) submission to the U.S. FDA in the second half of 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Guggenheim Bullish on Core Drug Obefazimod's Prospects, Assigns 'Buy' Rating to Abivax (ABVX.US)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGuggenheim Bullish on Core Drug Obefazimod's Prospects, Assigns 'Buy' Rating to Abivax (ABVX.US)\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-29 15:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Prior to French biotech firm Abivax (ABVX.US) releasing data on its core drug obefazimod, investment bank Guggenheim raised the company's target stock price from $150 to $175 and assigned a \"Buy\" rating. Analyst Yatin Suneja stated that this adjustment is based on optimistic prospects for the upcoming 44th-week maintenance period data readout of its core drug obefazimod. On December 15, Abivax announced its Q3 2025 financial results. The company reported revenue of $2.4 million, exceeding market expectations by $1.06 million. However, the quarterly net loss per share totaled $1.68. The company's net loss for the first nine months widened to €254.1 million, up from €136.9 million in the same period of 2024. The company's financial activities reflect an increased focus on its lead drug candidate, obefazimod, a first-in-class oral miR-124 enhancer. Research and development expenses rose to €133.4 million, primarily driven by advancements in the ABTECT Phase III program for ulcerative colitis and the ENHANCE-CD Phase IIb trial for Crohn's disease. Abivax is gearing up for several key milestones in 2026. The primary results of the ABTECT maintenance trial are expected to be announced in Q2 2026, which will provide the final clinical basis for the planned New Drug Application (NDA) submission to the U.S. FDA in the second half of 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1154069927","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1154069927","pubTimestamp":1766991791,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Prior to French biotech firm Abivax (ABVX.US) releasing data on its core drug obefazimod, investment bank Guggenheim raised the company's target stock price from $150 to $175 and assigned a \"Buy\"...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ABVX":"Abivax S.A."},"translate_title":"古根海姆看好核心药物Obefazimod的前景，给予Abivax(ABVX.US)“买入”评级","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABVX":1},"content_text":"Prior to French biotech firm Abivax (ABVX.US) releasing data on its core drug obefazimod, investment bank Guggenheim raised the company's target stock price from $150 to $175 and assigned a \"Buy\" rating. Analyst Yatin Suneja stated that this adjustment is based on optimistic prospects for the upcoming 44th-week maintenance period data readout of its core drug obefazimod. On December 15, Abivax announced its Q3 2025 financial results. The company reported revenue of $2.4 million, exceeding market expectations by $1.06 million. However, the quarterly net loss per share totaled $1.68. The company's net loss for the first nine months widened to €254.1 million, up from €136.9 million in the same period of 2024. The company's financial activities reflect an increased focus on its lead drug candidate, obefazimod, a first-in-class oral miR-124 enhancer. Research and development expenses rose to €133.4 million, primarily driven by advancements in the ABTECT Phase III program for ulcerative colitis and the ENHANCE-CD Phase IIb trial for Crohn's disease. Abivax is gearing up for several key milestones in 2026. The primary results of the ABTECT maintenance trial are expected to be announced in Q2 2026, which will provide the final clinical basis for the planned New Drug Application (NDA) submission to the U.S. FDA in the second half of 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}